RxDoctor Payments Data

Brandon Hardin, DO

Family Medicine · Murfreesboro, TNNPI 1235691676

Payments from drug & device makers

$4,050in general payments, 2019–2025

Across 204 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$496
  • AstraZeneca$468
  • Novo Nordisk$454
  • Merck$313
  • Boston Scientific$287
  • Amgen$274
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,050 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$92,227
Medicare patients
301
Services billed
3,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$108,254
JardianceEmpagliflozin102$90,577
EliquisApixaban89$79,011
FarxigaDapagliflozin Propanediol67$51,603
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,093
LinzessLinaclotide16$15,722
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$14,241
TrulicityDulaglutide11$11,694
Breo ElliptaFluticasone/Vilanterol17$9,759
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,276
XareltoRivaroxaban12$8,172
GemtesaVibegron12$7,426
Xigduo XrDapaglifloz Propaned/Metformin18$6,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,818
Icosapent Ethyl11$3,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$454$108,25493 claims
Boehringer IngelheimJardiance$57$90,577102 claims
PfizerEliquis$197$79,01189 claims
AstraZenecaFarxiga, Breztri Aerosphere$468$65,84485 claims
GSKTrelegy Ellipta, Breo Ellipta$264$25,85242 claims
AbbVieLinzess, Synthroid$496$17,40242 claims
Lilly USA, LLCTrulicity$79$11,69411 claims
Sumitomo Pharma America, Inc.Gemtesa$39$7,42612 claims
Sanofi-aventis U.S. LLCLantus$53$1,86417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →